ISIDLB1777 - A Novel Ex Vivo Model of Human Hair Follicle Immune Privilege Collapse Reveals the Potential of Farudodstat, a DHODH Inhibitor, as a Therapeutic for Alopecia Areata Treatment
May 2023
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study explores the potential of farudodstat, a DHODH inhibitor, as a treatment for alopecia areata (AA), an inflammatory disorder characterized by immune privilege (IP) collapse in hair follicles. Using an innovative ex vivo model, healthy human hair follicles were stimulated to mimic AA conditions, resulting in increased T-cell proliferation and MHC expression, indicating IP loss. Treatment with 140 nM farudodstat significantly reduced T-cell proliferation and MHC expression without inducing catagen or affecting keratinocyte proliferation, suggesting it may protect against IP collapse without cytotoxic effects. These findings propose farudodstat as a promising therapeutic option for AA.
